Cargando…

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature

Mucopolysaccharidosis type II (MPS II) is a multisystemic lysosomal storage disorder caused by deficiency of the iduronate 2-sulfatase enzyme. Currently, enzyme replacement therapy (ERT) with recombinant idursulfase is the main treatment available to decrease morbidity and improve quality of life. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gragnaniello, Vincenza, Carraro, Silvia, Rubert, Laura, Gueraldi, Daniela, Cazzorla, Chiara, Massa, Pamela, Zanconato, Stefania, Burlina, Alberto B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248226/ https://www.ncbi.nlm.nih.gov/pubmed/35782619 http://dx.doi.org/10.1016/j.ymgmr.2022.100878

Ejemplares similares

Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2020)

Bone disease in early detected Gaucher Type I disease: A case report
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Review of the use of idursulfase in the treatment of mucopolysaccharidosis II
por: Burrow, T Andrew, et al.
Publicado: (2008)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

Newborn Screening for Fabry Disease: Current Status of Knowledge
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria
por: Burlina, Alessandro P., et al.
Publicado: (2020)

Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study
por: Burlina, Alessandro P., et al.
Publicado: (2019)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy
por: Burlina, Alberto B., et al.
Publicado: (2019)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
por: Hogan, Melissa J., et al.
Publicado: (2020)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Abnormal activation of MAPKs pathways and inhibition of autophagy in a group of patients with Zellweger spectrum disorders and X-linked adrenoleukodystrophy
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Newborn screening for Pompe disease in Italy: Long-term results and future challenges
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience
por: Gragnaniello, Vincenza, et al.
Publicado: (2021)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Unusual Evolution of Hypertrophic Cardiomyopathy in Non-Compaction Myocardium in a Pompe Disease Patient
por: Gragnaniello, Vincenza, et al.
Publicado: (2023)

Comparative study of idursulfase beta and idursulfase in vitro and in vivo
por: Kim, Chihwa, et al.
Publicado: (2017)

A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry
por: Racoma, Marie Julianne C., et al.
Publicado: (2021)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II
por: Kim, Katherine H., et al.
Publicado: (2014)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration
por: Chung, Jou-Ku, et al.
Publicado: (2016)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
por: Yee, Karen S., et al.
Publicado: (2023)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Congenital hyperinsulinism in clinical practice: From biochemical pathophysiology to new monitoring techniques
por: Martino, Mariangela, et al.
Publicado: (2022)

Quality of Life (QoL) assessment in a cohort of patients with Phenylketonuria
por: Cazzorla, Chiara, et al.
Publicado: (2014)

Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II
por: Ngu, Lock-Hock, et al.
Publicado: (2017)

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2019)

Timing of Food Introduction and the Risk of Food Allergy
por: Ferraro, Valentina, et al.
Publicado: (2019)

Impact of COVID-19 in Children with Chronic Lung Diseases
por: Ferraro, Valentina Agnese, et al.
Publicado: (2022)

Metabolomics Applied to Pediatric Asthma: What Have We Learnt in the Past 10 Years?
por: Ferraro, Valentina Agnese, et al.
Publicado: (2023)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
por: Chan, Mei-Yan, et al.
Publicado: (2023)

Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2022)

Correction: Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria
por: Manti, Filippo, et al.
Publicado: (2023)

Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria
por: Burlina, Alberto, et al.
Publicado: (2016)

Psychosocial impact of Covid-19 outbreak on Italian asthmatic children and their mothers in a post lockdown scenario
por: Di Riso, Daniela, et al.
Publicado: (2021)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Nitric Oxide and Biological Mediators in Pediatric Chronic Rhinosinusitis and Asthma
por: Ferraro, Valentina Agnese, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_admkho6v70tcanucrnatresnhm